Search clinical trials for: Dapagliflozin 10 MG

Total 12694 results

Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, France, Germany, Italy, United States, Argentina, Czechia, Vietnam, Peru, China, Philippines, Austria, Canada, Japan, Malaysia, Poland, Taiwan, Thailand, Brazil, Finland, Greece, Israel, Mexico, United Kingdom, Turkey, Colombia, Slov... and more
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
AstraZeneca

Recruiting

Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease. (MIRO-CKD)

Chronic Kidney Disease

Spain, Italy, China, Vietnam, United States, Brazil, Canada, Malaysia, Poland, Taiwan, Austria, Bulgaria, Chile, United Kingdom, Japan
Beijing Anzhen Hospital

Recruiting

The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.

Coronary Artery Disease | Diabete Mellitus

China
University of Turin, Italy

Unknown

Antidiuretic Function Before and During Treatment With SGLT2 Inhibitors (GliRACo1)

Diabetes Mellitus, Type 2 | Body Weight Changes | Arterial Hypertension

Italy
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Abramson Cancer Center of the University of Pennsylvania

Terminated

Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia (UPCC04407)

Acute Myeloid Leukemia

United States
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Zhongshan Hospital Xiamen University

Unknown

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Diabetic Nephropathy | Type 2 Diabetes

China
Medical University of Vienna
Vienna Dialysis Center

Recruiting

SGLT2 Inhibition in Hemodialysis (DAPA-HD)

Diabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular Hypertrophy

Austria
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fed Conditions

Healthy Subjects

Canada
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Completed

Bioequivalence of Dapagliflozin 10 mg Tablets Under Fasting Conditions

Healthy Subjects

Canada
Fundación Pública Andaluza para la Investigación...

Unknown

SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease

Type 2 Diabetes Mellitus

Spain
AstraZeneca

Terminated

Safety and Efficacy of Dapagliflozin in Asian T2DM Subjects With Inadequate Glycemic Control on Metformin/Saxagliptin

Type 2 Diabetes Mellitus

Thailand, Vietnam
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
Collegium Medicum w Bydgoszczy

Recruiting

Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment (DEMETER)

Metabolic Syndrome

Poland
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
Maastricht University
AstraZeneca

Completed

Effects of 2 Weeks Treatment With Dapagliflozin in Subjects With an Impaired Glucose Homeostasis on Nocturnal Substrate Oxidation (MaasFlex)

Prediabetic State | Substrate Oxidation

Netherlands
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Substance-Related Disorders | Depression | HIV Infections

United States
Spanish Society of Cardiology
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III

Active, not recruiting

Dapagliflozin After Transcatheter Aortic Valve Implantation (DapaTAVI)

Aortic Stenosis | Transcatether Aortic Valve Implantation

Spain
Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
Holbaek Sygehus

Enrolling by invitation

Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment (PRESERVE)

End Stage Renal Disease | Peritoneal Dialysis Complication

Denmark
George Clinical Pty Ltd
University Medical Center Groningen; Ground Zero Pharmaceuticals

Unknown

An Open Label Phase IV Study to Evaluate Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Impaired Renal Function

Diabetes Mellitus, Type 2 | Impaired Renal Function

Canada
Dong-A University

Recruiting

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Renal Insufficiency, Chronic | Percutaneous Coronary Intervention | Cardiac Catheterization

Korea, Republic of
University of Campinas, Brazil
AstraZeneca

Completed

Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery (ADDENDA)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Carotid Artery Diseases

Brazil
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
Northwestern University
National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...

Recruiting

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Heart Failure | Kidney Diseases | Chronic Kidney Diseases | Heart Failure With Preserved Ejection Fraction

United States
Tor Biering-Sørensen

Recruiting

Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients With CKD (DECODE-CKD)

Chronic Kidney Diseases

Denmark
Chang Gung Memorial Hospital

Active, not recruiting

Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation

Catheter Ablation | Atrial Fibrillation Recurrent

Taiwan
Hongchang Guo

Recruiting

Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac Surgery

Diabetes Mellitus, Type 2 | Cardiac Surgery

China
AstraZeneca
Bristol-Myers Squibb; Hadassah Medical Organization; The TIMI Study Group

Completed

Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events (DECLARE-TIMI58)

Diabetes Mellitus, Non-Insulin-Dependent | High Risk for Cardiovascular Event

United States, Canada, France, Italy, Netherlands, Spain, Belgium, Thailand, Vietnam, Bulgaria, Korea, Republic of, Brazil, Philippines, Russian Federation, Turkey, Taiwan, Australia, Israel, South Africa, Germany, Japan, Czechia, H... and more
AstraZeneca
Parexel; George Clinical Pty Ltd

Terminated

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

Chronic Kidney Disease

United States, Taiwan, Germany, Hungary, Malaysia, Japan, Israel, Poland, Brazil, Ukraine, Argentina
Hospital General Universitario Gregorio Marañon
Instituto de Salud Carlos III; University of Navarra; Fundación para la Investigación...

Unknown

Effects of SGLT2 Inhibition on the Mechanisms of Cardiac Damage in the Diabetic Patient With HFpEF (CARDIA-STIFF)

Diabetes Mellitus, Type 2 | Heart Failure With Preserved Ejection Fraction

Spain
University Health Network, Toronto

Recruiting

The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK)

Kidney Transplant Recipients

Canada
Nanjing First Hospital, Nanjing Medical University

Unknown

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Oslo University Hospital
Karolinska University Hospital; Aarhus University Hospital; Erasmus Medical Center and other collaborators

Recruiting

DAPAgliflozin for Renal Protection in Heart Transplant Recipients (DAPARHT)

Kidney Failure | Heart Transplant Failure

Netherlands, Sweden, Denmark, Norway
Mads Ersbøll

Recruiting

Dapagliflozin in Pulmonary Arterial Hypertension (DAPAH)

Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary Hypertension

Denmark

Search clinical trials for: Dapagliflozin 10 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations